Megacystis-Microcolon-Intestinal Hypoperistalsis Syndrome 2 (MMIHS2): A Comprehensive Disease Characteristics Report

Disease: Megacystis-Microcolon-Intestinal Hypoperistalsis Syndrome 2 MONDO ID: MONDO:0025708 | OMIM: 619431 | Causal gene: MYH11 (HGNC:7569) Category: Mendelian (autosomal recessive)

Evidence source note: This report is compiled from aggregated disease-level resources (OMIM, Orphanet, HGNC/Ensembl/UniProt/gnomAD) and primary literature (human clinical case series/cohorts, mouse models, in vitro/immunohistochemical studies, and computational constraint data). Because MMIHS2 is ultra-rare, most human evidence derives from case reports and small cohorts; MMIHS-wide cohort statistics (which are dominated by ACTG2 cases) are used where MYH11-specific numbers are unavailable and are flagged as such.

Summary

Megacystis-Microcolon-Intestinal Hypoperistalsis Syndrome 2 (MMIHS2) is a rare, severe congenital visceral myopathy caused by autosomal-recessive biallelic loss-of-function (LOF) variants in MYH11, the gene encoding smooth-muscle myosin heavy chain (SM myosin II) — the dominant motor protein that drives smooth-muscle-cell contraction. Loss of functional SM myosin abolishes contractility in the smooth muscle of the urinary bladder and gastrointestinal tract, producing the defining triad from birth: a massively distended, non-obstructed urinary bladder (megacystis), an unused, small-caliber microcolon, and intestinal hypo- or aperistalsis causing a functional (non-mechanical) intestinal obstruction. MMIHS2 is the MYH11-linked subtype within the broader MMIHS family, which also includes the more common ACTG2-related form (MMIHS type 1, OMIM 155310) and rarer recessive forms caused by LMOD1, MYLK, MYL9, and the candidate gene PDCL3.

Mechanistically, MMIHS2 is a "contractile apparatus" disease: all confirmed MMIHS genes encode components of the smooth-muscle thin/thick filament and the myosin-light-chain-kinase (MLCK) phosphorylation axis. Biallelic MYH11 null alleles remove or drastically reduce the myosin motor itself, so the smooth muscle cannot generate force despite the presence of normal enteric ganglion cells and interstitial cells of Cajal. This distinguishes MMIHS from Hirschsprung disease (a neuropathic aganglionosis) and classifies it among the "variants of Hirschsprung's disease" — congenital smooth-muscle-cell disorders. Notably, routine histopathology and electron microscopy of MYH11 visceral myopathy are often near-normal, underscoring that the defect is functional rather than grossly structural.

Clinically, MMIHS shows a striking female preponderance (~70–73%), is frequently detected on prenatal ultrasound (megacystis ± polyhydramnios), and historically carried a very poor prognosis (survival <20% in older series). Modern management — total parenteral nutrition (TPN), intestinal rehabilitation, bladder catheterization/vesicostomy, enteric stomas, and isolated-intestinal or multivisceral (± liver) transplantation — has raised survival to roughly 55–65%, with patients now living into the second and third decades of life. There is no effective disease-specific pharmacotherapy; treatment is entirely supportive/surgical, with transplantation the only definitive option once TPN-associated liver failure develops. This report synthesizes 9 confirmed findings across 26 reviewed papers into a complete disease-characteristics knowledge-base entry.

Section 1. Disease Information

Overview. MMIHS (Berdon syndrome) is a congenital disorder of impaired smooth-muscle contractility producing functional obstruction of the bladder and bowel. MMIHS2 designates the subtype caused by biallelic MYH11 variants. It is the most severe form of functional intestinal obstruction in the newborn (PMID: 18280270).

Key identifiers.

Synonyms / alternative names. Berdon syndrome; Berdon's syndrome; MMIHS; congenital visceral myopathy (MMIHS subtype); megacystis–microcolon–intestinal hypoperistalsis syndrome type 2.

Information source. Content here is derived from aggregated disease-level resources (OMIM, Orphanet, HGNC/Ensembl/UniProt) plus individual-patient and small-cohort clinical reports and systematic reviews. It is not derived from a large EHR/population registry, reflecting the disease's rarity.

Section 2. Etiology

Primary cause — genetic. MMIHS2 is caused by biallelic (homozygous or compound heterozygous) loss-of-function variants in MYH11 (Finding F001). This is a monogenic Mendelian cause; there is no established environmental, infectious, or acquired etiology.

Evidence: - A homozygous nonsense variant c.3598A>T (p.Lys1200Ter) was identified by exome sequencing in a newborn with MMIHS and prune-belly phenotype from consanguineous parents (PMID: 25407000): "We performed exome sequencing in a newborn with MMIHS and prune belly phenotype whose parents are consanguineous and identified a homozygous variant (c.3598A>T: p.Lys1200Ter) in MYH11, which codes for the smooth muscle myosin heavy chain." - Compound heterozygous variants c.2051G>A (p.R684H) and c.3540_3541delinsTT (p.(E1180D,Q1181Ter)) were found in a Chinese family, with a marked decrease in MYH11 protein on Western blot (PMID: 31427716): "Trio-targeted exome sequencing identified compound heterozygous variants, c.2051 G > A (p.R684H) and c.3540_3541delinsTT (p.(E1180D, Q1181Ter)), in MYH11." - A 16p13.11 microdeletion encompassing MYH11 unmasked a missense p.Pro127Ser variant on the other allele, confirming a biallelic null mechanism (PMID: 31044419): "Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS), a rare condition that affects smooth muscle cells, is caused by biallelic null alleles in MYH11."

Genetic risk factors. The causal variants are the risk factor. Consanguinity is a major contributor (multiple index cases arose from consanguineous unions), consistent with an autosomal-recessive rare-allele architecture. MYH11 is highly intolerant to LOF in the general population (Finding F008): gnomAD constraint pLI ≈ 1.0; observed/expected LoF = 80/246.6 (o/e = 0.32, 90% CI 0.27–0.39; LOEUF ≈ 0.39); LoF Z = 9.0; missense Z = 3.29 — i.e., strong depletion of both LoF and missense variants. This intolerance explains the dual disease architecture of MYH11: heterozygous dominant-negative or protein-elongating variants cause thoracic aortic aneurysm/dissection and a dominant dysmotility syndrome, while biallelic null alleles cause recessive MMIHS2.

Environmental risk factors / protective factors / gene–environment interactions. Not applicable / none identified. As a fully penetrant Mendelian disorder driven by biallelic null alleles, no environmental risk factors, protective factors, lifestyle exposures, or gene–environment interactions have been described. Sex is a phenotype-modifying factor (female predominance and worse outcomes in girls) rather than a causal risk factor.

Section 3. Phenotypes

All phenotypes are congenital/neonatal in onset, severe, and stable-to-progressive (organ damage accrues secondary to chronic obstruction and TPN). HPO terms below were verified against EBI OLS4/HPO (Finding F009).

Important negative: Aganglionic megacolon / Hirschsprung disease (HP:0002251) is NOT a feature — enteric ganglia are present in MMIHS2 (Finding F009). This is a key differential-diagnostic point.

Quality-of-life impact. Profound. Affected individuals are typically dependent on parenteral nutrition and require bladder drainage (intermittent catheterization or vesicostomy) and enteric stomas from birth. Chronic complications include TPN-associated cholestatic liver disease, recurrent sepsis, and chronic kidney disease (PMID: 41591435). Disease-specific formal QoL instrument data (EQ-5D/SF-36/PROMIS) are not available for this ultra-rare condition.

Section 4. Genetic / Molecular Information

Causal gene. MYH11 — "myosin heavy chain 11" (smooth muscle) — HGNC:7569, NCBI Gene 4629, Ensembl ENSG00000133392, UniProt P35749, gene-OMIM 160745, located at 16p13.11 (Finding F007).

Pathogenic variants (MMIHS2 = recessive, biallelic).

• Classification: Pathogenic/likely pathogenic per ACMG (nonsense/frameshift LOF; missense-unmasked-by-deletion). All are exceedingly rare in population databases.
• Variant types: Nonsense, frameshift/delins, missense, and whole-gene deletion (CNV) — all converging on a loss-of-function / biallelic-null mechanism.
• Allele frequency: All variants are ultra-rare; MYH11 is strongly LoF-constrained in gnomAD (Finding F008), so these alleles are essentially private/family-specific.
• Origin: Germline, inherited from carrier (often consanguineous) parents.
• Functional consequence: Loss of function — absent or markedly reduced SM myosin heavy chain (confirmed by Western blot in PMID: 31427716).

Contrast — dominant MYH11 variants (NOT MMIHS2). Heterozygous dominant-negative MYH11 variants cause familial thoracic aortic aneurysm/dissection, and protein-elongating heterozygous variants (e.g., c.5819_5820insCA p.Gln1941Asnfs91; c.5819del p.Pro1940Hisfs91) cause a dominant severe smooth-muscle dysmotility syndrome via a distinct "dominant hypercontractile loss-of-function" mechanism (PMID: 31944481). MMIHS2 specifically requires biallelic null alleles.

Genetic heterogeneity of MMIHS (related genes). ACTG2 (dominant, most common), and recessive LMOD1, MYLK, MYL9, plus candidate PDCL3 (PMID: 28602422, PMID: 29453416, PMID: 32621347, PMID: 38461165). Approximately 10% of cases lack a variant in known genes, implying further loci.

Modifier genes / epigenetics / chromosomal abnormalities. No specific modifier genes are established for MMIHS2. Sex acts as a phenotype modifier (see Sections 3, 9, 11). No disease-specific epigenetic mechanism is described. A 16p13.11 microdeletion encompassing MYH11 is a relevant structural abnormality that can contribute one null allele (PMID: 31044419).

Section 5. Environmental Information

Not applicable. MMIHS2 is a monogenic recessive disorder. No environmental factors, toxins, radiation, occupational exposures, lifestyle factors, or infectious agents are known to cause or trigger it. (Recurrent bacterial sepsis occurs as a complication of chronic TPN/central lines and bacterial translocation, not as an etiologic agent — see Sections 11–12.)

Section 6. Mechanism / Pathophysiology

Ordered causal chain

1. Biallelic loss-of-function variants in MYH11 (nonsense, frameshift, missense-over-deletion; germline, recessive) lead to absent or markedly reduced smooth-muscle myosin heavy chain (SM myosin II) protein. (Demonstrated — homozygous/compound-het LOF; Western blot shows reduced protein.)
2. Loss of SM myosin II results in failure to assemble functional thick filaments in the smooth-muscle contractile apparatus, so myosin cannot engage actin thin filaments to generate force. (Inferred from protein function; SMII is "the dominant motor protein driving SMC contraction.")
3. Absent myosin motor activity leads to loss of smooth-muscle contraction in the detrusor (bladder) and intestinal muscularis propria. (Demonstrated functionally; mechanistically inferred.) 4a. Bladder branch: Detrusor failure results in a non-contractile, massively distended bladder (megacystis) → leads to upstream hydroureter and hydronephrosis, and (chronically) chronic kidney disease. (Demonstrated clinically/radiologically.) 4b. Intestinal branch: Muscularis failure results in intestinal hypo-/aperistalsis (intestinal pseudo-obstruction) → the unused distal bowel remains small-caliber (microcolon) and the proximal bowel distends (abdominal distention). (Demonstrated.)
4. Functional intestinal obstruction leads to inability to feed enterally → TPN dependence → TPN-associated cholestatic liver disease, sepsis, and multi-organ failure, the principal causes of death. (Demonstrated clinically.)

Key qualifier: enteric ganglion cells are present and normal, and routine histology/EM of MYH11 visceral myopathy is often near-normal with preserved MYH11 immunostaining — the lesion is functional (motor deficit) rather than a gross structural loss of smooth muscle (PMID: 36571289): "Apart from non-specific changes (e.g., muscle hypertrophy and distension-related muscularis propria necrosis), no alterations were identified by routine histopathological evaluation or electron microscopy."

Mechanistic detail

Molecular pathway / contractile apparatus (Finding F004). MYH11 encodes SM myosin II, described as "the dominant motor protein driving SMC contraction" (PMID: 42094517). The MMIHS gene set — ACTG2, MYH11, LMOD1, MYLK, MYL9 — collectively encodes proteins of the thin/thick-filament and MLCK-phosphorylation axis; "MYLK, LMOD1, MYL9, and MYH11 encode for various proteins within smooth muscle cells; abnormalities within these proteins lead to abnormal intestinal smooth muscle contractions" (PMID: 31848803). The physiologic contraction cascade is: Ca²⁺/calmodulin → MLCK (MYLK) phosphorylates regulatory myosin light chain (MYL9) → activated SM myosin (MYH11) cross-bridges with γ-smooth-muscle actin (ACTG2), stabilized by leiomodin (LMOD1). MMIHS2 removes the motor itself.

Cellular process. Failure of smooth-muscle-cell contraction (the core defect). Downstream, chronic distension produces non-specific muscle hypertrophy and distension-related muscularis propria necrosis (PMID: 36571289).

Protein dysfunction. Loss of function of SM myosin heavy chain — reduced/absent protein rather than a toxic aggregate. (Contrast: dominant MYH11 disease uses dominant-negative or hypercontractile mechanisms — PMID: 31944481.)

Immune involvement. None primary. Recurrent sepsis is secondary to catheters/TPN and bacterial translocation.

Tissue-damage mechanisms. Mechanical over-distension → ischemia/necrosis of muscularis; secondary uropathy (hydronephrosis → CKD) and TPN-associated cholestatic hepatopathy.

Suggested ontology terms. - GO biological process: smooth muscle contraction (GO:0006939); regulation of smooth muscle contraction (GO:0006940); myosin filament assembly (GO:0031034); muscle filament sliding (GO:0030049). - GO molecular function: microfilament motor activity (GO:0000146); actin binding (GO:0003779). - GO cellular component: myosin filament (GO:0032982); contractile fiber (GO:0043292); myosin II complex (GO:0016460). - CL cell types: smooth muscle cell (CL:0000192); smooth muscle cell of the bladder / visceral smooth muscle cell (CL:0000514). - CHEBI: calcium(2+) (CHEBI:29108); ATP (CHEBI:15422).

Section 7. Anatomical Structures Affected

Organ level. - Primary: Urinary bladder (UBERON:0001255) → megacystis; large intestine/colon (UBERON:0001155) → microcolon; small intestine (UBERON:0002108) → hypoperistalsis. - Secondary: Ureter (UBERON:0000056) → hydroureter; kidney (UBERON:0002113) → hydronephrosis, chronic kidney disease; liver (UBERON:0002107) → TPN-associated cholestasis. - Body systems: Digestive/gastrointestinal and urinary (renal) systems are primary.

Tissue and cell level. - Tissue: visceral (smooth) muscle — muscularis propria of gut and detrusor of bladder (UBERON:0001135 smooth muscle tissue). - Cell population: visceral smooth muscle cells (CL:0000192 smooth muscle cell; CL:0000514 smooth muscle cell of the bladder/visceral). Enteric neurons/ganglia and interstitial cells of Cajal are spared (normal).

Subcellular level. - Contractile apparatus / myosin filament (GO:0032982), contractile fiber (GO:0043292), actomyosin cytoskeleton (GO:0042641). The primary compartment is the contractile cytoskeleton, not mitochondria/nucleus/ER/lysosome.

Localization / laterality. Bilateral and diffuse — both the entire lower urinary tract and the intestinal tract are affected symmetrically (a systemic visceral myopathy, not a focal lesion).

Section 8. Temporal Development

Onset. Congenital. Megacystis and polyhydramnios are detectable prenatally (megacystis on antenatal ultrasound; bowel findings may appear late in gestation — PMID: 15543490). ~63–65% of cases are identified by prenatal imaging (PMID: 27421821). Symptoms manifest as neonatal functional bowel obstruction with distended bladder and microcolon in essentially all patients (PMID: 26413901).

Onset pattern. Chronic/congenital from birth (not acute or relapsing).

Progression. The primary smooth-muscle defect is stable (fixed genetic lesion), but the disease course is progressive because of accumulating secondary organ injury — TPN-associated liver disease, chronic kidney disease from chronic uropathy, and recurrent sepsis. Disease duration is lifelong; there is no self-limited course and no spontaneous remission.

Critical periods / intervention windows. The neonatal period is critical for diagnosis and establishment of bladder drainage, enteral/parenteral nutrition, and enteric diversion. Preventing TPN-associated liver failure defines the window for considering isolated intestinal transplant before multivisceral/liver transplant becomes necessary (PMID: 41591435).

Section 9. Inheritance and Population

Epidemiology. MMIHS is ultra-rare (no precise prevalence/incidence per 100,000 is established; Orphanet ORPHA:2241). Systematic reviews aggregate ~227 total cases across the literature since 1976 (PMID: 21792650); MMIHS2 (MYH11) is a small minority of these, most published as individual families.

Inheritance (MMIHS2). Autosomal recessive, biallelic null (Finding F001). Consanguinity is a recurring feature. Penetrance appears complete for biallelic null genotypes; expressivity varies (sex-associated severity differences). No genetic anticipation (not a repeat-expansion disorder). No established germline mosaicism or founder effect specific to MYH11 MMIHS2. Carrier frequency is very low, consistent with strong gnomAD LoF constraint (Finding F008); heterozygous carriers of MYH11 null alleles are generally unaffected for MMIHS (though other heterozygous MYH11 variant classes cause dominant aortic/dysmotility disease).

Population demographics. - Sex ratio: Strong female preponderance (Findings F003, F005). Across 227 cases, "A clear preponderance for female infants was found (female 70.6 vs. male 29.4%)" (PMID: 21792650); a 121–135-patient review found "73% (88/121) of the patients were female" (PMID: 27421821). In an ACTG2 cohort (n=103), girls had higher rates of microcolon (p=0.009), PN dependency (p=0.003), and death/transplant (p=0.029) (PMID: 35149643). - Geographic/ethnic distribution: No specific endemic distribution; cases reported worldwide (e.g., consanguineous kindreds, a Chinese family, a Japanese nationwide cohort). Consanguineous populations are over-represented for recessive forms. - Age distribution: Present at birth; historically few survived beyond infancy, though survivors now reach the second–third decade (oldest historical survivor 24 years).

Section 10. Diagnostics

Clinical/imaging. Diagnosis rests on the clinico-radiological triad: distended non-obstructed bladder (megacystis) + microcolon + intestinal hypoperistalsis, often with hydronephrosis/hydroureter and malrotation. Imaging (prenatal ultrasound, then neonatal radiographs, contrast studies, ultrasound, MRI) is central; the radiologist frequently first suggests the diagnosis and later monitors for mechanical obstruction vs dysmotility, CKD, and TPN-cholestasis (PMID: 41591435).

Biopsy / histopathology. Full-thickness intestinal biopsy shows present, normal ganglion cells (excluding Hirschsprung) and often near-normal muscle on routine histology/EM, with only non-specific changes (hypertrophy, distension necrosis) and preserved MYH11 immunostaining (PMID: 36571289, PMID: 26413901). Histology alone is therefore insufficient — genetic testing is required for subtype assignment.

Genetic testing (definitive for MMIHS2). - Recommended approach: NGS gene panel or exome sequencing covering ACTG2, MYH11, LMOD1, MYLK, MYL9 (± PDCL3), plus chromosomal microarray (CMA) to detect CNVs such as 16p13.11 deletions unmasking a MYH11 allele (PMID: 38461165, PMID: 31044419). - WES/WGS successfully identified the founding MYH11 variants (PMID: 25407000); trio/targeted exome identified compound-het variants (PMID: 31427716). - Karyotyping/FISH have limited utility except for detecting large structural changes; mitochondrial DNA and repeat-expansion testing are not applicable.

Biomarkers / omics. No specific circulating biomarker exists. Western blot for MYH11 protein and cDNA analysis are research/confirmatory tools. No validated metabolomic/proteomic diagnostic signature.

Clinical criteria / differential diagnosis. Differential includes Hirschsprung disease (distinguished by aganglionosis — HP:0002251, absent in MMIHS2), other visceral myopathies/CIPO, ACTG2/LMOD1/MYLK/MYL9 MMIHS subtypes, prune-belly syndrome, and mechanical obstruction. MMIHS is formally classified among "variants of Hirschsprung's disease" (congenital smooth-muscle-cell disorders with present ganglia) (PMID: 23943250).

Screening. Prenatal ultrasound (megacystis/polyhydramnios) is the de facto screen. Carrier and cascade screening for at-risk families and prenatal/preimplantation genetic testing are available once the family's biallelic MYH11 variants are known.

Section 11. Outcome / Prognosis

Survival/mortality.

Modern management (TPN, intestinal rehabilitation, multivisceral transplant) now allows survival into the second decade of life (PMID: 41591435). Overall modern survival is roughly 55–65%. Main causes of death are "sepsis, malnutrition and multiple organ failure" (PMID: 21792650).

Morbidity/function. Very high: lifelong PN dependence, bladder drainage, enteric stomas; chronic complications include TPN-cholestatic liver disease, CKD, and recurrent sepsis. Disability is substantial.

Complications. Sepsis, malnutrition/multiple-organ failure (leading causes of death); TPN-associated liver failure; chronic kidney disease.

Prognostic factors. Female sex predicts worse outcomes (higher microcolon, PN dependence, death/transplant — PMID: 35149643); early onset (<2 y) associates with full MMIHS features. Development of TPN-liver failure is a key adverse prognostic event driving transplant need. Successful transplantation can restore enteral autonomy (PMID: 23167913).

Section 12. Treatment

No disease-specific pharmacotherapy exists (Finding F006). In the Japanese cohort, "although various medications were given, the patients did not show significant improvement" (PMID: 26413901). Prokinetics and related drugs are ineffective because the defect is the absence of the myosin motor itself. Management is supportive and surgical:

Nutritional / supportive. - Total parenteral nutrition (TPN) and intestinal rehabilitation — mainstay for enteral failure (NCIT: Total Parenteral Nutrition). 16/19 patients required PN in the Japanese cohort (PMID: 26413901). - Prophylactic antibiotics for urinary/enteric infection.

Urologic. - Clean intermittent catheterization or vesicostomy for bladder drainage (30% [22/73] had vesicostomy) (PMID: 27421821) (NCIT: Vesicostomy; Intermittent Catheterization).

Enteric/surgical diversion. - Gastrostomy, ileostomy, jejunostomy for decompression/venting (PMID: 27421821) (NCIT: Gastrostomy; Ileostomy).

Transplantation (definitive). - Isolated intestinal transplantation restored enteral autonomy: "We report an eight-yr-old patient with MMIHS who was treated with isolated intestinal transplantation. She had completely oral intake during the four yr of follow-up" (PMID: 23167913) (NCIT: Intestinal Transplantation). - Combined living-related liver + bowel transplantation restored enteral autonomy when TPN-liver failure developed (PMID: 18280270) (NCIT: Liver Transplantation; Multivisceral Transplantation). - Multivisceral transplantation used when TPN-associated liver failure supervenes; ~15% (18/116) of patients received intestinal/multivisceral transplant (PMID: 27421821).

Advanced / experimental therapeutics. No approved gene therapy, cell therapy, RNA-based, targeted, or immunotherapy exists for MMIHS2. Given the biallelic-null LOF mechanism, gene-replacement strategies are conceptually attractive but remain experimental/preclinical. No pharmacogenomic guidance applies.

Treatment strategy. Neonatal stabilization → bladder drainage + enteric diversion + PN → intestinal rehabilitation → transplantation if PN fails or TPN-liver disease develops. Personalized care depends on genetic confirmation for counseling and family planning.

Section 13. Prevention

Because MMIHS2 is a fully penetrant recessive Mendelian disorder, prevention is genetic/reproductive, not lifestyle-based.

• Primary prevention: Not achievable by risk-factor modification. Genetic counseling for consanguineous/at-risk couples; carrier testing once family variants are known; prenatal diagnosis and preimplantation genetic testing (PGT) to prevent recurrence.
• Secondary prevention: Prenatal ultrasound detection of megacystis/polyhydramnios enables early diagnosis and planning (PMID: 15543490, PMID: 27421821).
• Tertiary prevention (complication avoidance): Meticulous line/TPN management to prevent sepsis and cholestatic liver disease; timely transplant referral; upper-urinary-tract protection to limit CKD (PMID: 41591435).
• Immunization / public-health / environmental interventions / prophylactic drugs: Not applicable to disease causation; standard infection prophylaxis applies to catheter/TPN care.
• Counseling: Genetic counseling is central — recurrence risk is 25% for future pregnancies of carrier couples; cascade testing offered to relatives.

Section 14. Other Species / Natural Disease

Orthologous genes (Finding F007; HomoloGene 128512):

Natural disease in animals. No well-characterized naturally occurring MYH11-MMIHS analog is documented in companion animals or wildlife (no established OMIA entry identified in this investigation). Comparative biology shows the smooth-muscle contractile pathway is deeply conserved across vertebrates, supporting mechanistic translation from model organisms. No zoonotic potential (genetic disease).

Section 15. Model Organisms

Mouse (Mus musculus) — the principal model (Finding F002). - A Myh11 knockout / haploinsufficiency mouse recapitulates core MMIHS features: "Myh11 deficiency leads to significant bladder enlargement, smooth muscle thickening, collagen accumulation, and voiding dysfunction, establishing a good disease model for MMIHS" (PMID: 41797110). - Earlier work cited by the founding human study noted that loss of Myh11 function in mice produces a bladder and intestinal phenotype "highly reminiscent of MMIHS" (PMID: 25407000).

Model types available. Constitutive knockout, haploinsufficient (heterozygous), and conditional/lineage models exist; Myh11-CreER driver lines are widely used for smooth-muscle-specific gene manipulation (e.g., Myh11CreER;Yy1fl/fl, Myh11CreER;Mettl3fl/fl — PMID: 40795179), and a CRISPR knock-in EGFP-SMII mouse enables live imaging of myosin filament dynamics (PMID: 42094517).

Phenotype recapitulation. Good for the bladder phenotype (megacystis, voiding dysfunction, muscle thickening, collagen accumulation). Recapitulation of the full microcolon / intestinal-aperistalsis triad and neonatal lethality is less completely characterized in the reviewed literature.

Limitations. Constitutive Myh11 null mice may have confounding vascular/aortic phenotypes (heterozygous MYH11 causes aortic disease), and mouse gut anatomy/physiology differs from human; the human microcolon feature and TPN-dependence course are not fully modeled.

Applications. Study of smooth-muscle contractile mechanics, bladder/voiding physiology, myosin-filament assembly dynamics, and preclinical testing of interventions.

In vitro / other systems. Rat aortic SMC lines (A7R5) and patient-derived approaches inform SMII biology; iPSC-derived smooth muscle and organoid models are plausible but not established for MMIHS2 in the reviewed literature. Resources: MGI, RGD, ZFIN, IMPC/IMSR.

Mechanistic Model / Interpretation

   Biallelic LOF variants in MYH11 (16p13.11)
   (nonsense / frameshift / missense-over-deletion; germline, recessive)
                     │  [Western blot: reduced MYH11 protein]
                     ▼
   Absent / reduced SM myosin II (the dominant SMC motor protein)
                     │  (no functional thick filaments to engage actin)
                     ▼
   Failure of smooth-muscle-cell CONTRACTION (functional, not structural)
        │                                            │
        ▼ (bladder branch)                           ▼ (gut branch)
   Detrusor fails --> MEGACYSTIS               Muscularis fails --> hypo/aperistalsis
        │                                            │
        ▼                                            ▼
   Hydroureter --> Hydronephrosis          MICROCOLON (unused bowel) +
        │                                   abdominal distention
        ▼                                            │
   Chronic kidney disease                            ▼
                                          Enteral failure --> TPN dependence
                                                       │
                                                       ▼
                                    TPN-cholestatic liver disease, SEPSIS,
                                    multi-organ failure --> leading cause of death
                                                       │
                                                       ▼
                                    Rescue: isolated intestinal / multivisceral
                                    (+/- liver) transplantation --> enteral autonomy

   NB: Enteric ganglia + interstitial cells of Cajal are NORMAL
       (distinguishes MMIHS from Hirschsprung disease).

Upstream vs downstream. The mutation → protein loss → contractile failure steps are upstream and demonstrated at the molecular level. The organ-level distension, microcolon, uropathy, and TPN-related complications are downstream, demonstrated clinically/radiologically. The gut and bladder branches are parallel consequences of the same single lesion.

Genotype–phenotype logic. MYH11 is a "double-hit-dependent" locus: heterozygous null carriers are unaffected for MMIHS (strong gnomAD LoF constraint reflects selection against other heterozygous variant classes that cause dominant aortic/dysmotility disease), while only biallelic null genotypes cause the recessive MMIHS2 visceral myopathy. This clean loss-of-function logic makes gene replacement a rational (though unproven) therapeutic direction.

Evidence Base

Limitations and Knowledge Gaps

1. Small case numbers. MMIHS2 (MYH11-specific) is described in a handful of families; most epidemiologic/survival statistics are drawn from mixed-genotype MMIHS cohorts (including the far more common ACTG2 form), so MYH11-specific prognosis and frequencies are extrapolated, not directly measured.
2. No precise prevalence/incidence for MMIHS2 exists; the disease is ultra-rare.
3. Female predominance is unexplained. The strong female skew (~70%) is well documented but mechanistically unresolved for a nominally autosomal-recessive condition; it may reflect ascertainment, X-linked/hormonal modifiers, or sex-specific smooth-muscle biology — none proven.
4. Mechanism step 2 (filament-assembly failure) is inferred, not directly demonstrated in patient tissue; histology is near-normal, so the functional deficit is deduced from protein loss and physiology.
5. Intestinal-branch modeling is incomplete. Mouse models robustly show the bladder phenotype; full microcolon/aperistalsis recapitulation is less characterized.
6. No biomarkers, no disease-specific drug, no gene/cell therapy — the therapeutic pipeline is empty beyond supportive care and transplantation.
7. Modifier genes and epigenetics for MMIHS2 severity are essentially unstudied.

Proposed Follow-up Experiments / Actions

1. Genotype-stratified natural-history study. Assemble a MYH11-specific MMIHS2 registry to derive subtype-specific survival, transplant rates, and complication timelines (vs ACTG2 and other genes).
2. Investigate the female-predominance mechanism. Test for X-linked or sex-hormone modifiers of visceral smooth-muscle contractility in Myh11-deficient mice of both sexes; re-examine ascertainment bias.
3. Complete the intestinal phenotype in models. Generate/characterize smooth-muscle-conditional Myh11 knockouts assessing colonic caliber, peristalsis (spatiotemporal mapping), and neonatal survival to fully model the triad.
4. Preclinical gene-replacement proof-of-concept. Given the clean biallelic-LOF mechanism, test AAV- or nanoparticle-delivered MYH11 restoration (or read-through agents for nonsense alleles such as p.Lys1200Ter) in patient-derived iPSC smooth-muscle/organoid systems and mouse models.
5. Biomarker discovery. Explore whether circulating SM-myosin fragments, urodynamic parameters, or bowel-motility signatures can serve as diagnostic/prognostic markers and transplant-timing tools.
6. Refine transplant timing. Compare outcomes of pre-emptive isolated intestinal transplant versus multivisceral (± liver) transplant after TPN-liver failure develops, to optimize the intervention window.
7. Prenatal-diagnosis optimization. Correlate prenatal megacystis/polyhydramnios findings with genetically confirmed MMIHS2 to improve early counseling and PGT uptake in at-risk families.

Report compiled from 9 confirmed findings and 26 reviewed papers. Evidence types span human clinical case reports and systematic reviews (majority), mouse model-organism studies (Myh11 KO/haploinsufficiency), in vitro smooth-muscle biology, and computational/population-genetics constraint data (gnomAD).